Clinical trial CLEAR
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR)
Cancers | |
---|---|
Organ | Kidney |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Eisai Limited |
EudraCT Identifier | 2016-000916-14 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02811861 |
Inclusion criteria | First line metastatic |
Last update |